CELU: financial statements from SEC — TradeAlmanac

CELU

Celularity Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	30 Sept 2025	30 Jun 2025	31 Mar 2025	30 Sept 2024	30 Jun 2024	31 Mar 2024
Revenue	5M	6M	11M	9M	12M	15M
Cost of revenue	4M	5M	4M	4M	2M	2M
Research and development	5M	3M	4M	4M	4M	6M
Selling, general and administrative	9M	13M	14M	13M	16M	14M
Operating income	−13M	−16M	−10M	−12M	−10M	−7M
Pre-tax income	−23M	−25M	−20M	−16M	−6M	−22M
Income tax	—	—	—	0	0	0
Net income	−23M	−25M	−20M	−16M	−6M	−22M
Earnings per share	−0.88	−1.02	−0.84	−0.73	−0.30	−1.03
Earnings per share, diluted	−0.88	−1.02	−0.84	−0.73	−0.30	−1.03
Weighted average shares	26M	24M	24M	22M	22M	21M
Weighted average shares, diluted	26M	24M	24M	22M	22M	21M

Balance sheet

Metric	31 Dec 2025	30 Sept 2025	30 Jun 2025	31 Mar 2025	31 Dec 2024	30 Sept 2024	30 Jun 2024	31 Mar 2024
Cash and equivalents	6M	120,000	863,000	293,000	738,000	10M	11M	12M
Inventory	571,000	3M	4M

Cash flow

Metric	31 Mar 2025	31 Mar 2024
Operating cash flow	−3M	−4M
Depreciation and amortisation	2M	2M
Capital expenditure	—	39,000
Investing cash flow	—	−39,000
Financing cash flow	2M	6M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator